A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult

PHASE2CompletedINTERVENTIONAL
Enrollment

3,854

Participants

Timeline

Start Date

December 30, 2020

Primary Completion Date

May 15, 2021

Study Completion Date

October 29, 2021

Conditions
Covid19 Vaccine
Interventions
BIOLOGICAL

MVC-COV1901(S protein with adjuvant)

Approximately 3180 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region

BIOLOGICAL

MVC-COV1901(Saline)

Approximately 530 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region

Trial Locations (12)

Unknown

Changhua Christian Hospital, Changhua

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

China Medical University Hospital, Taichung

National Cheng Kung University Hospital, Tainan City

National Taiwan University Hospital, Taipei

Taipei Medical University Hospital, Taipei

Taipei Municipal Wan Fang Hospital, Taipei

Taipei Veteran General Hospital, Taipei

Tri-Service General Hospital, Taipei

Chang-Guang Memorial Hospital Lin-Kou, Taoyuan District

Tao-Yuan General Hospital, Taoyuan District

National Institute of Hygiene and Epidemiology, Hanoi

All Listed Sponsors
lead

Medigen Vaccine Biologics Corp.

INDUSTRY

NCT04695652 - A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult | Biotech Hunter | Biotech Hunter